Losmapimod
FIS-002-2019 OLE
Phase 3 small_molecule terminated
Quick answer
Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD) is a Phase 3 program (small_molecule) at Fulcrum Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Fulcrum Therapeutics
- Indication
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated